Literature DB >> 33585253

Elucidating the Consequences of Heparan Sulfate Binding by Heparanase 2.

Miriam Gross-Cohen1, Sari Feld1, Gil Arvatz1, Neta Ilan1, Israel Vlodavsky1.   

Abstract

Unlike the intense research effort devoted to exploring the significance of heparanase in human diseases, very little attention was given to its close homolog, heparanase 2 (Hpa2). The emerging role of Hpa2 in a rare autosomal recessive congenital disease called urofacial syndrome (UFS), clearly indicates that Hpa2 is not a pseudogene but rather a gene coding for an important protein. Hpa2 lacks the heparan sulfate (HS)-degrading activity typical of heparanase, yet exhibits high affinity to HS, affinity that is 10-fold higher than that of heparanase. The consequences of this high-affinity interaction of Hpa2 with plasma membrane HSPG has not been explored yet. Here, we used highly purified Hpa2 protein to examine this aspect. We provide evidence that cells adhere to and spread on dishes coated with Hpa2. We also show that cell migration is attenuated markedly by exogenous addition of Hpa2 to primary and transformed cells, a function that agrees with the anti-cancer properties of Hpa2. Interestingly, we found that exogenous addition of Hpa2 also disrupts the morphology of cell colonies, resulting in cell scattering. This implies that under certain conditions and experimental settings, Hpa2 may exhibit pro-tumorigenic properties. We further developed a panel of anti-Hpa2 monoclonal antibodies (mAb) and show that these properties of Hpa2 are prevented by some of the newly-developed mAb, thus providing new molecular tools to better appreciate the significance of Hpa2 in health and disease.
Copyright © 2021 Gross-Cohen, Feld, Arvatz, Ilan and Vlodavsky.

Entities:  

Keywords:  adhesion; heparan sulfate; heparanase; heparanase 2; migration; scattering

Year:  2021        PMID: 33585253      PMCID: PMC7879983          DOI: 10.3389/fonc.2020.627463

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  59 in total

1.  Urinary tract effects of HPSE2 mutations.

Authors:  Helen M Stuart; Neil A Roberts; Emma N Hilton; Edward A McKenzie; Sarah B Daly; Kristen D Hadfield; Jeffery S Rahal; Natalie J Gardiner; Simon W Tanley; Malcolm A Lewis; Emily Sites; Brad Angle; Cláudia Alves; Teresa Lourenço; Márcia Rodrigues; Angelina Calado; Marta Amado; Nancy Guerreiro; Inês Serras; Christian Beetz; Rita-Eva Varga; Mesrur Selcuk Silay; John M Darlow; Mark G Dobson; David E Barton; Manuela Hunziker; Prem Puri; Sally A Feather; Judith A Goodship; Timothy H J Goodship; Heather J Lambert; Heather J Cordell; Anand Saggar; Maria Kinali; Christian Lorenz; Kristina Moeller; Franz Schaefer; Aysun K Bayazit; Stefanie Weber; William G Newman; Adrian S Woolf
Journal:  J Am Soc Nephrol       Date:  2014-08-21       Impact factor: 10.121

2.  Heparanase and Chemotherapy Synergize to Drive Macrophage Activation and Enhance Tumor Growth.

Authors:  Udayan Bhattacharya; Lilach Gutter-Kapon; Tal Kan; Ilanit Boyango; Uri Barash; Shi-Ming Yang; JingJing Liu; Miriam Gross-Cohen; Ralph D Sanderson; Yuval Shaked; Neta Ilan; Israel Vlodavsky
Journal:  Cancer Res       Date:  2019-11-05       Impact factor: 12.701

Review 3.  Transmembrane signaling proteoglycans.

Authors:  John R Couchman
Journal:  Annu Rev Cell Dev Biol       Date:  2010       Impact factor: 13.827

4.  Activity-based probes for functional interrogation of retaining β-glucuronidases.

Authors:  Liang Wu; Jianbing Jiang; Yi Jin; Wouter W Kallemeijn; Chi-Lin Kuo; Marta Artola; Wei Dai; Cas van Elk; Marco van Eijk; Gijsbert A van der Marel; Jeroen D C Codée; Bogdan I Florea; Johannes M F G Aerts; Herman S Overkleeft; Gideon J Davies
Journal:  Nat Chem Biol       Date:  2017-06-05       Impact factor: 15.040

5.  Inhibition of matrix metalloproteinase-2 expression and bladder carcinoma metastasis by halofuginone.

Authors:  M Elkin; R Reich; A Nagler; E Aingorn; M Pines; N de-Groot; A Hochberg; I Vlodavsky
Journal:  Clin Cancer Res       Date:  1999-08       Impact factor: 12.531

6.  A mouse model of urofacial syndrome with dysfunctional urination.

Authors:  Chunming Guo; Satoshi Kaneko; Ye Sun; Yichen Huang; Israel Vlodavsky; Xiaokun Li; Zhong-Rong Li; Xue Li
Journal:  Hum Mol Genet       Date:  2014-12-15       Impact factor: 6.150

Review 7.  Heparanase regulation of cancer, autophagy and inflammation: new mechanisms and targets for therapy.

Authors:  Ralph D Sanderson; Michael Elkin; Alan C Rapraeger; Neta Ilan; Israel Vlodavsky
Journal:  FEBS J       Date:  2016-11-16       Impact factor: 5.542

8.  Heparanase enhances myeloma progression via CXCL10 downregulation.

Authors:  U Barash; Y Zohar; G Wildbaum; K Beider; A Nagler; N Karin; N Ilan; I Vlodavsky
Journal:  Leukemia       Date:  2014-04-04       Impact factor: 11.528

9.  A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours.

Authors:  Keith Dredge; Todd V Brennan; Edward Hammond; Jason D Lickliter; Liwen Lin; Darryn Bampton; Paul Handley; Fleur Lankesheer; Glynn Morrish; Yiping Yang; Michael P Brown; Michael Millward
Journal:  Br J Cancer       Date:  2018-03-13       Impact factor: 7.640

10.  Heparanase 2, mutated in urofacial syndrome, mediates peripheral neural development in Xenopus.

Authors:  Neil A Roberts; Adrian S Woolf; Helen M Stuart; Raphaël Thuret; Edward A McKenzie; William G Newman; Emma N Hilton
Journal:  Hum Mol Genet       Date:  2014-04-01       Impact factor: 6.150

View more
  2 in total

1.  Induction of heparanase 2 (Hpa2) expression by stress is mediated by ATF3.

Authors:  Ibrahim Knani; Preeti Singh; Miriam Gross-Cohen; Sharon Aviram; Neta Ilan; Ralph D Sanderson; Ami Aronheim; Israel Vlodavsky
Journal:  Matrix Biol       Date:  2021-11-20       Impact factor: 11.583

2.  Expanding the HPSE2 Genotypic Spectrum in Urofacial Syndrome, A Disease Featuring a Peripheral Neuropathy of the Urinary Bladder.

Authors:  Glenda M Beaman; Filipa M Lopes; Aybike Hofmann; Wolfgang Roesch; Martin Promm; Emilia K Bijlsma; Chirag Patel; Aykut Akinci; Berk Burgu; Jeroen Knijnenburg; Gladys Ho; Christina Aufschlaeger; Sylvia Dathe; Marie Antoinette Voelckel; Monika Cohen; Wyatt W Yue; Helen M Stuart; Edward A Mckenzie; Mark Elvin; Neil A Roberts; Adrian S Woolf; William G Newman
Journal:  Front Genet       Date:  2022-06-23       Impact factor: 4.772

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.